Snake Cathelicidin NA-CATH and Smaller Helical Antimicrobial Peptides Are Effective against *Burkholderia thailandensis*

Ryan J. Blower¹, Stephanie M. Barksdale¹, Monique L. van Hoek¹,² *

¹ George Mason University, School of Systems Biology, Manassas, Virginia, United States of America,
² George Mason University, National Center for Biodefense and Infectious Diseases, Manassas, Virginia, United States of America

* mvanhoek@gmu.edu

**Abstract**

*Burkholderia thailandensis* is a Gram-negative soil bacterium used as a model organism for *B. pseudomallei*, the causative agent of melioidosis and an organism classified category B priority pathogen and a Tier 1 select agent for its potential use as a biological weapon. *Burkholderia* species are reportedly “highly resistant” to antimicrobial agents, including cyclic peptide antibiotics, due to multiple resistance systems, a hypothesis we decided to test using antimicrobial (host defense) peptides. In this study, a number of cationic antimicrobial peptides (CAMPs) were tested *in vitro* against *B. thailandensis* for both antimicrobial activity and inhibition of biofilm formation. Here, we report that the Chinese cobra (*Naja atra*) cathelicidin NA-CATH was significantly antimicrobial against *B. thailandensis*. Additional cathelicidins, including the human cathelicidin LL-37, a sheep cathelicidin SMAP-29, and some smaller ATRA peptide derivatives of NA-CATH were also effective. The D-enantiomer of one small peptide (ATRA-1A) was found to be antimicrobial as well, with EC₅₀ in the range of the L-enantiomer. Our results also demonstrate that human alpha-defensins (HNP-1 & -2) and a short beta-defensin-derived peptide (Peptide 4 of hBD-3) were not bactericidal against *B. thailandensis*. We also found that the cathelicidin peptides, including LL-37, NA-CATH, and SMAP-29, possessed significant ability to prevent biofilm formation of *B. thailandensis*. Additionally, we show that LL-37 and its D-enantiomer D-LL-37 can disperse pre-formed biofilms. These results demonstrate that although *B. thailandensis* is highly resistant to many antibiotics, cyclic peptide antibiotics such as polymyxin B, and defending peptides, some antimicrobial peptides including the elapid snake cathelicidin NA-CATH exert significant antimicrobial and antibiofilm activity towards *B. thailandensis*.

**Author Summary**

*Burkholderia* species such as *B. pseudomallei*, which causes melioidosis, and the model organism *B. thailandensis* are extremely resistant to antibiotics, including cyclic peptide antibiotics such as polymyxin B. Treatment for *Burkholderia* infections is impeded by this...
resistance, and new approaches are needed. We hypothesized that the cathelicidin NA-CATH from the Chinese cobra, *Naja atra*, and smaller derivative peptides (ATRA peptides) may have antimicrobial activity against *Burkholderia*. We therefore tested the bactericidal effects of the cathelicidin and its derivative peptides. We also wanted to determine whether the antimicrobial peptides exert anti-biofilm activity, although the role of biofilm as a critical virulence factor of *Burkholderia* has not yet been established. We found that the peptide ATRA-1A, as well as the stereo-isomer D-ATRA-1A, were able to kill *B. thailandensis*, and the full-length snake cathelicidin NA-CATH was able to both kill *B. thailandensis* and inhibit its biofilm formation, unlike the human-alpha defensin peptides HNP-1 and HNP-2, and the small peptide derived from hBD3. These results show that the NA-CATH antimicrobial peptide possess bactericidal and anti-biofilm activity against *B. thailandensis*, and suggest that these compounds should be tested for their effect against the more virulent strains of *Burkholderia*.

**Introduction**

*Burkholderia pseudomallei* is a Gram-negative soil bacterium which acts as a facultative intracellular pathogen that can infect both humans and animals, causing melioidosis. Melioidosis is endemic to Southeast Asia and Northern Australia, where the mortality rates are 50% and 19% respectively [1–3]. In addition, *B. pseudomallei* is of interest because it is considered a class B priority pathogen and has potential for aerosol delivery. In this study, *Burkholderia thailandensis* is used as a model for *B. pseudomallei* [4]. *B. thailandensis* is a BSL-2 organism closely related to *B. pseudomallei* with an LD50 in mice 1000-fold higher than that of *B. pseudomallei*, making it an easier and safer model organism with which to work [5]. *B. thailandensis* has been successfully demonstrated to be a useful BSL-2 surrogate for *B. pseudomallei* [4,6–8] for both *in vitro* and *in vivo* experiments. Thus, *B. thailandensis* may be a good model in which to study the molecular actions of full length cathelicidins such as LL37 both as antibacterial and antibiofilm peptides against *Burkholderia* strains.

In *B. pseudomallei* and *B. thailandensis* the significant resistance towards several categories of antibiotics, including chloramphenicol, quinolones, tetracyclines, and trimethoprim, is mediated by the overexpression of efflux pumps [9,10]. *B. pseudomallei* and *B. thailandensis* are typically grown in the laboratory in the presence of >100 mg/ml polymyxin B [11]; such ready growth indicates their high level of resistance to cyclic peptide antibiotics. In fact, the genus *Burkholderia* is said to have “extreme antimicrobial peptide and polymyxin B resistance” [12]. Therefore, the discovery of novel therapeutic alternatives is urgently required.

We have previously studied the cathelicidin peptide from the elapid snake *Naja atra* and designed smaller peptide derivatives called ATRA peptides; we reported that these peptides were highly active against both Gram-positive and Gram-negative bacteria, such as Gram-positive *Staphylococcus aureus* and Gram-negative *Pseudomonas aeruginosa* [13–16]. We were very interested to know whether *B. thailandensis* would be susceptible to other antimicrobial peptides, and particularly to the very effective cathelicidin peptide (NA-CATH) and smaller peptide derivatives from elapid snakes that we had been studying.

Cationic antimicrobial peptides (CAMPs) are produced as part of the innate immune system by higher-order organisms. These peptides are also referred to as host-defense peptides (HDPs). CAMPs are low-molecular-weight, cationic, and often amphipathic peptides, and their overall positive charge enables association with the negatively charged bacterial outer membrane [17]. In this study, we tested two types of CAMPs: the cathelicidin type and the defensin type.
It has been previously reported that Burkholderia species, specifically *B. cepacia*, are very resistant to beta-defensins, a category of defensin CAMPs [18]. Defensins function by replacing Ca$^{2+}$ and Mg$^{2+}$ ions in the bacterial membrane, disrupting membrane stability and leading to loss of electric potential and eventual cell lysis [19,20]. Defensins are important to consider because they are found in human skin under inflammatory conditions [21] and could potentially play a role during a wound infection by *B. pseudomallei*. In this study, we tested the antibacterial activity of two alpha-defensins and a small peptide from beta-defensin against *B. thailandensis*.

Cathelicidins are a class of antimicrobial peptide characterized by a highly conserved cathelin domain [22] and a sequence-variable active cathelicidin domain. The majority of cathelicidin peptides form amphipathic alpha helices when in contact with a membrane, and these helices are believed to play a crucial role in their function [23,24]. Recently a cathelicidin, designated NA-CATH, has been discovered in *Naja atra*, the Chinese cobra [25], an elapid snake found in Southeast Asia [26]. This cathelicidin contains an imperfect repeated 11-amino-acid motif named the ATRA motif (Table 1) [13]. The first repeat is called ATRA-1 and the second repeat ATRA-2 [13]. A derivative, ATRA-1A, was created by replacing the 3rd residue of ATRA-1 with an alanine [13]. In previous work we demonstrated that the full-length cathelicidin (NA-CATH) and peptides based on the first repeat (ATRA-1 and ATRA-1A) were effective broad-spectrum antimicrobial agents against *Francisella novicida*, *Aggregatibacter actinomycetemcomitans*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* [13–16]. Therefore, the *Naja atra* cathelicidin NA-CATH and its ATRA derivatives were chosen for studies against *Burkholderia* species [10]. It is of note that we previously demonstrated that the cathelicidins LL-37, D-LL-37, NA-CATH, and NA-CATH derivatives cause no hemolysis at the antimicrobial concentrations used in our study [13,14]. This leads us to suggest that these peptides may be very useful as a potential new therapeutic approach, perhaps in a topical application, by virtue of their demonstrated antimicrobial action and minimal host-cell cytotoxicity, with the D-peptides having the added advantage of less susceptibility to protease digestion.

**Methods**

**Bacterial cells**

*B. thailandensis* (E264) was obtained from the American Type Culture Collection (Manassas, VA), ATCC 700388, and grown in nutrient broth overnight in a shaking incubator at 37°C. Cultures of *B. thailandensis* were grown up and the stocks were aliquotted, frozen at 20% glycerol, and stored at -80°C. Cultures were enumerated by serial dilution on nutrient agar.
Antimicrobial assays

The antimicrobial activity of various antimicrobial peptides against *B. thailandensis* was determined as previously described [16]. Briefly, in a sterile 96-well plate, 1x10^5 CFU per well of bacteria were incubated with serial dilutions of antibiotic (control) and peptide in 10 mM phosphate buffer (3 h, 37°C). Bacterial survival was then determined by serial dilution at each peptide concentration in sterile PBS. Dilutions were plated in triplicate on nutrient agar and incubated at 37°C for 24 h; colonies were then counted to determine survival. Bacterial survival was calculated by the ratio of the number of colonies on each experimental plate to the average number of colonies in the control plates lacking any antimicrobial peptide.

The antimicrobial peptide concentration required to kill 50% of *B. thailandensis* (EC50) was determined by graphing percent survival versus log of peptide concentration (log μg/ml). Data were plotted using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA). Survival was determined as the ratio of colonies from experimental plates relative to the average number of colonies from plates lacking peptide. EC50 was determined by fitting the data to a standard sigmoidal dose-response curve. Each experiment was performed three times with three replicates per experiment for n = 9. Error is reported as 95% confidence intervals (CI) for each antimicrobial peptide.

Biofilm inhibition assays

Biofilm was grown and measured as previously described [27–29]. Modified Vogel and Bonner’s medium (MVBM) [30] was inoculated from an overnight culture of *B. thailandensis* and allowed to incubate for 18 h in a shaking incubator at 37°C. The optical density at 540 nm (OD_{540}) was adjusted to 0.8 OD_{540}. Bacterial suspension (100 μl) was added to wells of a sterile tissue-culture-treated 96-well plate along with various concentrations of peptide and fresh MVBM (final volume 200 μl). Wells containing only medium or no peptide served as negative and positive controls, respectively. Plates were then incubated aerobically at 37°C for 3 h. Following aerobic adhesion, supernatant fluid was removed from wells (to remove planktonic bacteria), fresh MVBM/peptide was added to each well (200 μl final volume), and plates were incubated for 21 h at 37°C. After incubation, supernatant was removed and replaced with 200 μL of fresh MVBM/peptide, then incubated at 37°C for an additional 24 h. This is described as a 48 h biofilm. After final incubation, the plate was read at OD600nm to measure bacterial growth, then washed, fixed, and stained with crystal violet as previously described [31]. Each assay was performed in triplicate and the experiment repeated three times for n = 9.

Biofilm dispersion assays

Biofilm dispersion assay was performed using *B. thailandensis* E264 (ATCC 700388) in 100 μL MVBM and was incubated 24h, 37°C. After allowing biofilm to form for 24h, the biofilm was treated with 10 μg peptide or 0 peptide and then incubated at 37°C for an additional 24h. The optical density was measured prior to staining to measure bacterial growth after 48h incubation. Eight wells were used for each peptide (n = 8). Production of biofilm was measured using crystal violet staining as described previously [31].

Protein ID numbers

Protein ID numbers were obtained from the UniProt protein database. The protein ID number of LL-37, the human cathelicidin, is P49913. The protein number for SMAP-29, the sheep cathelicidin, is P49928. The protein number for NA-CATH, the cathelicidin from the Chinese King Cobra, is B6S2X0.
Results

Cathelicidin peptides demonstrate antimicrobial effects against *B. thailandensis*

In this study, we demonstrated the effectiveness of various snake-derived cathelicidin peptides against *B. thailandensis*, including NA-CATH. Control peptides included SMAP-29 and LL-37 (Table 2). Ceftazidime is the first-line antibiotic against *B. pseudomallei* [32]. Therefore, it was used as a positive control for observing a bactericidal effect in the antimicrobial plating assay. We determined the first-line antibiotic ceftazidime to have an EC50 value of 0.328 μM (95% CI of 0.20–0.548 μM) (Fig 1).

We found that the *Naja atra* peptide NA-CATH had EC50 values of 0.877 μM (95% CI of 0.61–1.26 μM) against *B. thailandensis*. This compared favorably to the sheep peptide SMAP-29, which was observed to have an EC50 value of 0.628 μM (95% CI of 0.194–2.03 μM). The human cathelicidin LL-37 was also found to have a good antimicrobial effect against *B. thailandensis*, with an EC50 value of 1.87 μM (95% CI of 1.20–2.94 μM). Data are presented in μMt to reflect the number of peptide molecules, thereby compensating for differing molecular weights. These results are consistent with the published values for the effect of LL-37 against *Burkholderia* [33–35]. These three cathelicidin peptides (NA-CATH, SMAP-29, LL-37) were not statistically different in their anti-*B. thailandensis* performance. The activity of LL-37 is similar to that shown for *B. pseudomallei* [34]. In previous work, these same cathelicidin peptides were tested against *P. aeruginosa, S. aureus*, and *F. novicida* [14–16]. We had expected *Burkholderia* species to have a higher EC50 than those organisms because of their wide range of mechanisms to evade destruction by antibiotics and antimicrobial peptides [10]. Surprisingly, the EC50 results against *B. thailandensis* were similar to cathelicidin EC50 values against other Gram-negative bacteria [14–16].

Small synthetic (ATRA) peptides derived from the *Naja atra* cathelicidin exhibited significant antimicrobial activity

*Naja atra* cathelicidin peptide derivatives were tested for antimicrobial activity against *B. thailandensis*. Each imperfect repeat from NA-CATH (ATRA-1 and ATRA-2) was tested, as well as the synthetic peptide ATRA-1A, in which amino acid 3 of ATRA-1 was switched from phenylalanine to alanine [13] [26]. The EC50 of ATRA-1 against *B. thailandensis* was determined to be 6.94 μM (95% CI of 4.26–11.3 μM) (Fig 2). EC50 plating assays determined that ATRA-2 was not an effective antimicrobial peptide, correlating with our previous ATRA-2 results with

| Peptide      | Molecular Weight (g/mol) | EC50 (μg/ml) | Confidence Interval (μg/ml) | EC50 (μM) | Confidence Interval (μM) |
|--------------|--------------------------|--------------|-----------------------------|-----------|--------------------------|
| Ceftazidime  | 636.6                    | 0.209        | 0.125–0.349                 | 0.328     | 0.20–0.548               |
| LL-37        | 4493.3                   | 8.43         | 5.37–13.2                   | 1.87      | 1.20–2.94               |
| SMAP-29      | 3256                     | 2.05         | 0.633–6.61                  | 0.628     | 0.194–2.03              |
| NA-CATH      | 4175.22                  | 3.66         | 2.55–5.26                   | 0.877     | 0.61–1.26               |
| ATRA-1       | 1497.92                  | 10.4         | 6.38–17.0                   | 6.94      | 4.26–11.3              |
| ATRA-1A      | 1420.84                  | 14.0         | 9.27–21.1                   | 9.83      | 6.52–14.8              |
| D-ATRA-1A    | 1420.84                  | 6.86         | 4.54–10.33                  | 4.82      | 3.20–7.27              |
| D-LL-37      | 4493.3                   | 16.4         | 9.16–29.4                   | 3.64      | 2.04–6.53              |

Scrambled LL-37, ATRA-2, and HNP-2 are not shown as no EC50 could be determined.

doi:10.1371/journal.pntd.0003862.t002
other bacteria [14–16]. This leads to the conclusion that the first imperfect repeat of NA-CATH contributes to most of the observed antimicrobial activity of NA-CATH. We then looked at a synthetic peptide, named ATRA-1A, which contains a single amino acid change at position 3 (F->A). This synthetic peptide exhibited an EC50 of 9.83 μM (95% CI of 6.52–14.8 μM).

D-amino acid stereoisomer forms of cathelicidin antimicrobial peptides exert antimicrobial activity against *B. thailandensis*

In previous work we demonstrated that peptides produced with each amino-acid in the D-form (enantiomer) can be antimicrobial [14,15,36]. In addition, peptides in the D-form are resistant to proteases such as trypsin [14,15,37,38]. Dean et al. demonstrated that while the L-form of the LL-37 peptide is digested by trypsin, the D-form shows no degradation after 1 h trypsin digestion [15]. Thus, we synthesized all-D-enantiomers of LL-37 and ATRA-1A to compare the antimicrobial activity of these protease-resistant enantiomers.

We found the antimicrobial effect of the D-enantiomer to be comparable to that of the L-enantiomer for both ATRA-1A and LL-37 (Fig 3). LL-37 had an EC50 value of 1.87 μM (95% CI of 1.20–2.94 μM), while D-LL-37 had a statistically similar EC50 of 3.64 μM (95% CI of
2.04–6.53 μM). D-ATRA-1A had an EC50 value of 4.82 μM (95% CI of 3.20–7.27 μM, as compared to 9.83 μM (95% CI of 6.52–14.8 μM) for ATRA-1A. For both enantiomeric conversions, the 95% confidence intervals of the D-peptide results overlapped those from the normal L version of the peptide. These data demonstrate that converting each peptide to an all-D-enantiomer did not statistically alter its antimicrobial effect.

Human alpha-and beta-defensins do not exert antimicrobial effects against *B. thailandensis*

We examined a second category of CAMPs, the defensins, for anti-*Burkholderia* activity. Under conditions of *B. pseudomallei* respiratory infection in mice, neutrophil granules were observed to be the predominant cell type seen in association with *B. pseudomallei* infection [39]. Neutrophil granules are known to be a significant source of cathelicidins and human neutrophil peptides (alpha-defensins) [40]. Therefore, to further explore the effect of defensins upon *B. thailandensis*, human alpha defensin-1 (aka human neutrophil peptide 1, HNP-1) and human alpha defensin-2 (HNP-2) were chosen as candidates to test for antimicrobial killing against *B. thailandensis* (Fig 4). For HNP-1, at the highest concentration tested (1000 μg/ml
peptide), only 65% killing could be achieved for *B. thailandensis*, suggesting that this is a highly ineffective peptide. HNP2 was even less effective than HNP1 in killing *B. thailandensis* at every concentration tested.

Sahly et al. demonstrated that the LD50 of human beta-defensin-3 (hBD-3) against multiple *Burkholderia* species was >100 μg/ml [18]. However, other reports demonstrated that regions of cationic peptides in the C-terminus of hBD-3 possessed antimicrobial activity against *E. coli* and *P. aeruginosa* [41,42]. Based on our previous work, we tested a small fragment (Peptide 4) of human beta-defensin 3 (hBD-3), which was previously shown to have significant activity against another Gram-negative bacterium, *E. coli* [42]. Incubation of *B. thailandensis* with Peptide 4 of hBD-3 at the highest concentration tested (1000 μg/ml) resulted in only 65% killing for *B. thailandensis*, suggesting that this is a highly ineffective peptide. These findings confirmed published reports [18,43] that the beta-defensin CAMPs are ineffective against *Burkholderia* species, and demonstrated that the alpha-defensins are also ineffective against *B. thailandensis*.

**Fig 3. Effect of D-enantiomer on antimicrobial activity.** *B. thailandensis* was incubated for 3 h with various peptide concentrations in 10 mM sodium phosphate buffer (pH 7.4); percent (%) survival was calculated as the ratio of CFUs before and after incubation. (A) EC50 for ATRA-1A and for D-ATRA-1A. (B) EC50 for LL-37 and D-LL-37.

doi:10.1371/journal.pntd.0003862.g003
Cathelicidin antimicrobial peptides inhibit biofilm formation

As *B. pseudomallei* has been reported to form biofilm [44,45], we sought to demonstrate the ability of various cathelicidins to inhibit biofilm formation in the model organism *B. thailandensis*. In addition, we and others have demonstrated that the cathelicidin LL-37 inhibits biofilm formation in *P. aeruginosa* [15,46], an important gram-negative pathogen. Therefore, a panel of cathelicidins was tested in biofilm inhibition assays. We first had to establish conditions under which the biofilm of *B. thailandensis* could be reliably formed and measured. To do this, we grew the bacteria in modified Vogel-Bonner medium (MVBM) [30] overnight and then adjusted OD$_{540}$ to 0.8. Following growth and measurement, a biofilm inhibition assay was performed. This assay incubates the test compound with the bacteria and determines if the compound can inhibit biofilm formation. The growth of bacteria is also measured to control for bactericidal effects of the test compound although bactericidal effects are reduced due to the high salt concentration of the media used in these assays. We demonstrated that the antibiotic ceftazidime did not inhibit biofilm production but simply killed the *B. thailandensis* (Fig 5), as we would expect. Interestingly, the cathelicidins LL-37, SMAP-29, and NA-CATH all showed at least 50% biofilm inhibition at peptide concentrations at or above 3 μg/ml. The negative control peptide, which was a scrambled LL-37 (same amino acid composition and net charge, different sequence of amino acids), did not inhibit biofilm, as we previously reported [14].
In addition, the D-enantiomers of the peptides were tested for their effect on biofilm inhibition. D-LL-37 produced results similar to those of its L-enantiomer. Both inhibited at least 50% of biofilm at concentrations as low as 3 μg/ml. Thus both the L- and D- form of LL-37 exhibit anti-biofilm activity against *B. thailandensis*. When the ATRA-1A enantiomers were
compared, the results differed slightly (S1 Fig). ATRA-1A did not inhibit biofilm formation, whereas D-ATRA-1A did slightly, but only at the highest concentration of peptide tested (300 μg/ml). At these levels, this is unlikely to be a significant activity of the D-ATRA-1A peptide. ATRA-1 and ATRA-2, the imperfect repeats from NA-CATH, were also tested for biofilm inhibition and did not inhibit biofilm formation (S1 Fig). Thus, the full-length cathelicidin peptides including the snake cathelicidin NA-CATH were able to inhibit *B. thailandensis* biofilm formation.

**LL-37 and its D-enantiomer D-LL-37 can disperse pre-formed biofilms**

We have demonstrated that some of our cathelicidins can inhibit biofilm formation in *B. thailandensis*. We wanted to know if these cathelicidin peptides could also disperse pre-formed biofilms. Therefore, a number of cathelicidins were chosen for the pre-formed biofilm dispersion assay as described in the methods. We demonstrated that LL-37 and D-LL-37 were able to disperse at least 50% of the pre-formed biofilm when 10 μg (11μM) peptide was added to 24h pre-formed biofilms (Fig 6), showing statistically equivalent activity. Other cathelicidins, SMAP-29 and NA-CATH (which demonstrated biofilm inhibition) did not demonstrate the ability to disperse pre-formed biofilms. Also, as expected, small NA-CATH derivative peptides (ATRA-1A, D-ATRA-1A, ATRA-2) showed no biofilm dispersion activity. The ability of D-LL-37 to disperse preformed *Burkholderia* biofilm has not been previously reported. These results suggest that LL-37 and D-LL-37 have a unique property that enables dispersion of preformed biofilm in this organism.

**Discussion**

*B. thailandensis* and *B. pseudomallei* have a wide range of mechanisms for evading antibiotics and antimicrobial peptides. These mechanisms include, but are not limited to, having a more impermeable membrane, multi-drug-resistant efflux pumps, inactivation of host proteins, and modification of drug targets [10]. In this study, we demonstrate that certain peptides can evade these mechanisms and exhibit antimicrobial activity against *B. thailandensis*, despite its reported extreme peptide resistance. We also demonstrate that D-amino acid peptides exhibit comparable antimicrobial activity [15]. Finally, we describe the anti-biofilm activity of some of these peptides against *B. thailandensis*.

The modes of action of CAMPs against bacteria are varied and require further elucidation; however, two potentially co-existing mechanisms exist. The first model is that these CAMPs cause the formation of transmembrane pores, causing dissolution of the membrane potential and eventual destruction of the bacterial cell [47]. A second proposed mechanism includes the internalization of the CAMP which can then bind to internal targets and interfere with cell wall synthesis [48]. In humans, only one cathelicidin has been identified: LL-37. This cathelicidin is released by proteolysis from the C-terminus of CAP18 protein [49]. The LL-37 cathelicidin, as well as other cathelicidins with similar alpha-helical structures, has been demonstrated to associate with the bacterial membrane and cause bacterial death [50,51]. The effective killing concentration of these alpha-helical cathelicidin-type CAMPs has driven the search for new cathelicidins. Recently, a cathelicidin has been discovered in the species *Naja atra*, the Chinese cobra [25,52] which is effective against multiple bacteria [13–16].

Previous reports indicated that LL-37 is antimicrobial against *B. thailandensis* and *B. pseudomallei*. It has been reported that 15 μM LL-37 in 1 mM potassium phosphate buffer (PPB) kills 10⁷ cfu/mL of *B. thailandensis* [35]. Another study with *B. thailandensis* demonstrated that 5 strains of *B. thailandensis* were >90% killed at concentrations of 12.5 mg/L or greater in 1 mM PPB [33]. We obtained the same result, but in this study we have reported our results in
terms of EC50 rather than lethal concentration. Research has also shown that LL-37 is effective at killing *B. pseudomallei*. One study reports that LL-37 effectively killed 24 strains of *B. pseudomallei* at a peptide concentration of 100 μM in 1 mM PPB [34], while another demonstrated >90% killing of 9 strains at concentrations of 6.25 mg/L (1.39 μM) or greater [33]. Under conditions of *B. pseudomallei* respiratory infection in mice, neutrophil granules were observed to be the predominant cell type seen in association with *B. pseudomallei* infection [39]. Since neutrophil granules are known to be a significant source of cathelicidins [40], our data and published results suggest a significant potential role of LL-37 expression during the infection of humans by *Burkholderia* species. We were able to demonstrate that LL-37, SMAP-29, NA-CATH, and small NA-CATH-derived ATRA peptides exert strong antimicrobial activity against *B. thailandensis*. Another group reported that the bovine cathelicidin BMAP-18 was antimicrobial against *B. pseudomallei* at 20 μM [53]. Together, these studies suggest that *B. thailandensis* and *B. pseudomallei* may be quite susceptible to cathelicidins as a class of peptides. A recent study also found that additional peptides, including the 12-aa peptide
bactenecin, the hybrid peptide CA-MA, and RTA3, were antimicrobial against \textit{B. pseudomallei} [53], suggesting that there are peptides that appear to be effective against this organism, particularly those with predominantly helical properties.

In addition, we addressed the potential issue of proteolytic degradation of AMPs \textit{in vivo} by bacterial proteases. Sieprawska-Lupa et al. demonstrated that mammalian hosts and numerous bacteria express proteases capable of degrading and inactivating LL-37 [54]. Therefore, we tested D-enantiomers, which we previously showed to be resistant to trypsin digestion [15], to compare their antimicrobial activity to that of the natural L-enantiomer. Our results show that for both LL-37 and ATRA-1A, the D-enantiomer exhibited antimicrobial activity comparable to that of the L-enantiomer, suggesting that bacterial proteases were not active against this peptide.

Our results also demonstrate that defensin peptides have at best a weak antimicrobial effect against \textit{Burkholderia}. Human beta-defensins had previously been shown to be ineffective against \textit{B. cepacia} or \textit{B. pseudomallei} [18,43]. The alpha-defensins HNP-1 and HNP-2 both demonstrated poor antimicrobial performance against \textit{B. thailandensis} in this work. For HNP-1, this is consistent with the literature on \textit{B. pseudomallei} [55,56]. (No previous work was found on HNP-2’s effect on \textit{Burkholderia pseudomallei}.) In addition, we tested HNP-3 and HNP-4 (Fig 4B) and found a similar lack of antimicrobial activity. This leads us to conclude that alpha-defensins in general do not exert strong antimicrobial activity against \textit{B. thailandensis}. A fragment of hBD3 (Peptide 4 from hBD3) was also ineffective against \textit{B. thailandensis}. Thus, \textit{Burkholderia} does seem to be highly resistant to both classes of defensins.

It has also been demonstrated that both \textit{B. thailandensis} and \textit{B. pseudomallei} form biofilms \textit{in vivo} [44,45], which may be a virulence factor [45]. We were able to demonstrate that the cathelicidins LL-37, D-LL-37, NA-CATH, and SMAP-29 are capable of biofilm inhibition in \textit{B. thailandensis} each at similar extents of \(~50\%) inhibition at 3 \(\mu\text{g}/\text{ml}\). This is in agreement with the published capability of LL-37 to inhibit biofilm formation in \textit{Pseudomonas} [46]. In addition, we demonstrated the new result of the ability of D-LL-37 to disperse pre-formed biofilms. Thus, the biofilm inhibition we demonstrate in this work may be a crucial component of the activity of cathelicidin-derived peptides as possible therapeutics.

Novel approaches to treatment for \textit{Burkholderia} infections are critically needed, especially for treatment of melioidosis. A novel peptide-based treatment for melioidosis would ideally include both antimicrobial activity and biofilm inhibition, and may take the form of a topical application. In this work, we have demonstrated the effects of LL-37, SMAP-29, and NA-CATH as both antimicrobial and anti-biofilm peptides, and showed promising results of short, synthetic peptides, such as ATRA1. We have also extended previous studies [35] showing here that an all-D-enantiomer of LL-37, which is resistant to proteolytic degradation, maintains antimicrobial activity as well as significant anti-biofilm properties against \textit{B. thailandensis}. The results of this study illustrating the susceptibility of \textit{B. thailandensis} to cathelicidin-like peptide killing, resistance to defensins, and the ability of D- and L-LL-37 peptides to inhibit biofilm formation may provide a new understanding of the potential use for peptides, perhaps as topical applications, in melioidosis infection.

**Supporting Information**

\textbf{S1 Fig. Biofilm activity of NA-CATH imperfect repeat derivatives against \textit{B. thailandensis}.} Minimal biofilm inhibition is demonstrated for \textbf{B.} D-ATRA-1A, while not biofilm inhibition is demonstrated for \textbf{A.} ATRA-1A, \textbf{C.} ATRA-1, and \textbf{D.} ATRA-2. Growth (absorbance at 600 nm) is shown by black bars; growth with no peptide was set to 100\%. Biofilm (gray bars) was detected on a polystyrene 96-well plate at 37°C after 48 h of growth in MVBM and detected as
absorbance of crystal violet stain (590 nm). Each experiment is representative of 3 individual experiments.

(TIF)

Acknowledgments

We thank Drs. B. Bishop and J. Schnur, GMU, for helpful discussions.

Author Contributions

Conceived and designed the experiments: RJB SMB MLvH. Performed the experiments: RJB. Analyzed the data: RJB SMB MLvH. Contributed reagents/materials/analysis tools: RJB SMB MLvH. Wrote the paper: RJB SMB MLvH.

References

1. Wiersinga WJ, Currie BJ, Peacock SJ (2012) Melioidosis. N Engl J Med 367: 1035–1044. doi: 10.1056/NEJMra1204699 PMID: 22970946
2. Limmathurotsakul D, Peacock SJ (2011) Melioidosis: a clinical overview. Br Med Bull 99: 125–139. doi: 10.1093/bmb/dr007 PMID: 21558159
3. Currie BJ, Ward L, Cheng AC (2010) The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4: e900. doi: 10.1371/journal.pntd.0000900 PMID: 21152057
4. Haraga A, West TE, Brittnacher MJ, Skerrett SJ, Miller SI (2008) Burkholderia thailandensis as a model system for the study of the virulence-associated type III secretion system of Burkholderia pseudomallei. Infect Immun 76: 5402–5411. doi:10.1128/IAI.00626-08 PMID: 18779342
5. Woods DE (1999) Species versus biotype status. J Clin Microbiol 37: 3786–3787. PMID: 10610379
6. West TE, Frevert CW, Liggitt HD, Skerrett SJ (2008) Inhalation of Burkholderia thailandensis results in lethal necrotizing pneumonia in mice: a surrogate model for pneumonic melioidosis. Trans R Soc Trop Med Hyg 102 Suppl 1: S119–126. doi: 10.1016/S0035-9203(08)70028-2 PMID: 19121672
7. Morici LA, Heang J, Tate T, Didier PJ, Roy CJ (2010) Differential susceptibility of inbred mouse strains to Burkholderia thailandensis aerosol infection. Microb Pathog 48: 9–17. doi: 10.1016/j.micpath.2009.10.004 PMID: 19853031
8. Brett PJ, DeShazer D, Woods DE (1998) Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol 48 Pt 1: 317–320.
9. Biot FV, Valade E, Garnotel E, Chevalier J, Villard C, et al. (2011) Involvement of the efflux pumps in chloramphenicol selected strains of Burkholderia thailandensis: pharmacologic and mechanistic evidence. PLoS One 6: e16892. doi: 10.1371/journal.pone.0016892 PMID: 21347382
10. Schweizer HP (2012) Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol 7: 1389–1399. doi: 10.2217/fmb.12.116 PMID: 23231488
11. Burtnick MN, Woods DE (1999) Isolation of polymyxin B-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin B resistance. Antimicrob Agents Chemother 43: 2646–2656. PMID: 10543742
12. Loutet SA, Valvano MA (2011) Extreme antimicrobial peptide and polymyxin B resistance in the genus Burkholderia. Front Cell Infect Microbiol 1: 6. doi: 10.3389/fcimb.2011.00006 PMID: 22919572
13. de Latour FA, Amer LS, Papanstasiou EA, Bishop BM, van Hoek ML (2010) Antimicrobial activity of the Naja atra cathelicidin and related small peptides. Biochem Biophys Res Commun 396: 825–830. doi: 10.1016/j.bbrc.2010.04.158 PMID: 20438706
14. Dean SN, Bishop BM, van Hoek ML (2011) Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol 11: 114. doi: 10.1186/1471-2180-11-114 PMID: 21605457
15. Dean SN, Bishop BM, van Hoek ML (2011) Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: D-enantiomer of LL-37. Front Microbiol 2: 128. doi: 10.3389/fmicb.2011.00128 PMID: 21772832
16. Amer LS, Bishop BM, van Hoek ML (2010) Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem Biophys Res Commun 396: 246–251. doi: 10.1016/j.bbrc.2010.04.073 PMID: 20399752
17. Hancock RE, Rozek A (2002) Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 206: 143–149. PMID: 11814654

18. Sahly H, Schubert S, Harder J, Rautenberg P, Ullmann U, et al. (2003) Burkholderia is highly resistant to human Beta-defensin 3. Antimicrob Agents Chemother 47: 1739–1741. PMID: 12709350

19. van Dijk A, Veldhuizen EJ, Haagsmen HP (2008) Avian defensins. Vet Immunol Immunopathol 124: 1–18. doi: 10.1016/j.vetimm.2007.12.006 PMID: 18313763

20. Sugirato H, Yu PL (2004) Avian antimicrobial peptides: the defense role of beta-defensins. Biochem Biophys Res Commun 323: 721–727. PMID: 15381059

21. Harder J, Bartels J, Christophers E, Schroder JM (2001) Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 276: 5707–5713. PMID: 11085990

22. Zanetti M (2004) Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 75: 39–48. PMID: 12960280

23. Gennaro R, Zanetti M (2000) Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 55: 31–49. PMID: 10931440

24. Yamashita H, Demizu Y, Shoda T, Sato Y, Oba M, et al. (2014) Amphipathic short helix-stabilized peptides with cell-membrane penetrating ability. Bioorg Med Chem 22: 2403–2408. doi: 10.1016/j.bmc.2014.03.005 PMID: 24661993

25. Wang ZY, Zhao Y, Ren L, Jin LH, Sun LP, et al. (2008) Novel gelatin-siloxane nanoparticles decorated by Tat peptide as vectors for gene therapy. Nanotechnology 19: 445103. doi: 10.1088/0957-4484/19/44/445103 PMID: 21832720

26. van Hoek ML (2014) Antimicrobial peptides in reptiles. Pharmaceuticals (Basel) 7: 723–753.

27. Sawasdidoln C, Taweechaisupapong S, Sermswan RW, Tattawasart U, Tungpradabkul S, et al. (2010) Growing Burkholderia pseudomallei in biofilm stimulating conditions significantly induces antimicrobial resistance. PLoS One 5: e9196. doi: 10.1371/journal.pone.0009196 PMID: 20169199

28. Ramli NS, Eng Guan C, Nathan S, Vadivelu J (2012) The effect of environmental conditions on biofilm formation of Burkholderia pseudomallei clinical isolates. PLoS One 7: e44104. doi: 10.1371/journal.pone.0044104 PMID: 22970167

29. Taweechaisupapong S, Kaewpa C, Arunyanart C, Kanla P, Homchampa P, et al. (2005) Virulence of Burkholderia pseudomallei does not correlate with biofilm formation. Microb Pathog 39: 77–85. PMID: 16084684

30. Lam J, Chan R, Lam K, Costerton JW (1980) Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 28: 546–556. PMID: 6772562

31. Durham-Colleran MW, Verhoeven AB, van Hoek ML (2010) Francisella novicida forms in vitro biofilms mediated by an orphan response regulator. Microb Ecol 59: 457–465. doi: 10.1007/s00248-009-9586-9 PMID: 19763680

32. Dance D (2014) Treatment and prophylaxis of melioidosis. Int J Antimicrob Agents 43: 310–318. doi: 10.1016/j.ijantimicag.2014.01.005 PMID: 24613038

33. Sim SH, Liu Y, Tan J, Thong TW, Wang D, et al. (2011) Antimicrobial activity of cathelicidin peptides against Burkholderia pseudomallei, the causative agent of melioidosis. Int J Antimicrob Agents 38: 270–271. doi: 10.1016/j.ijantimicag.2011.06.002 PMID: 21782393

34. Kanthawong S, Nazmi K, Wongratanacheewin S, Bolscher JG, Wuthiekanun V, et al. (2009) In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides. Int J Antimicrob Agents 34: 309–314. doi: 10.1016/j.ijantimicag.2009.05.012 PMID: 19577435

35. Kanthawong S, Bolscher JG, Veerman EC, van Marle J, Nazmi K, et al. (2010) Antimicrobial activities of LL-37 and its truncated variants against Burkholderia thailandensis. Int J Antimicrob Agents 36: 447–452. doi: 10.1016/j.ijantimicag.2010.06.031 PMID: 20685090

36. Juba M, Porter D, Dean S, Gillmor S, Bishop B (2013) Characterization and performance of short cationic antimicrobial peptide isomers. Biopolymers 100: 387–401. doi: 10.1002/bip.22244 PMID: 23532931

37. Wade D, Boman A, Wahlin B, Drain CM, Andreu D, et al. (1990) All-D amino acid-containing channel-forming antibiotic peptides. Proc Natl Acad Sci U S A 87: 4761–4765. PMID: 1693777

38. Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, et al. (2005) Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 174: 4271–4278. PMID: 15778390

39. Laws TR, Smither SJ, Lukaszewski RA, Atkins HS (2011) Neutrophils are the predominant cell-type to associate with Burkholderia pseudomallei in a BALB/c mouse model of respiratory melioidosis. Microb Pathog 51: 471–475. doi: 10.1016/j.micpath.2011.07.002 PMID: 21798336
40. Pinheiro da Silva F, Medeiros MC, Dos Santos AB, Ferreira MA, Garippo AL, et al. (2013) Neutrophils LL-37 migrate to the nucleus during overwhelming infection. Tissue Cell 45: 318–320. doi: 10.1016/j.tice.2013.04.003 PMID: 23742816

41. Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J (2003) Antimicrobial characterization of human beta-defensin 3 derivatives. Antimicrob Agents Chemother 47: 2804–2809. PMID: 12936977

42. Papanastasiou EA, Hua Q, Sandouk A, Son UH, Christenson AJ, et al. (2009) Role of acetylation and charge in antimicrobial peptides based on human beta-defensin-3. APMIS 117: 492–499. doi: 10.1111/j.1600-0463.2009.02460.x PMID: 19594489

43. Tandhavanant S, Thanwisai A, Limmathurotsakul D, Korbsrisate S, Day NP, et al. (2010) Effect of colony morphology variation of Burkholderia pseudomallei on intracellular survival and resistance to antimicrobial environments in human macrophages in vitro. BMC Microbiol 10: 303. doi: 10.1186/1471-2180-10-303 PMID: 21114871

44. Vorachit M, Lam K, Jayanetra P, Costerton JW (1995) Electron microscopy study of the mode of growth of Pseudomonas pseudomallei in vitro and in vivo. J Trop Med Hyg 98: 379–391. PMID: 8544219

45. Koh SF, Tay ST, Puthucheary SD (2009) Colonial morphotypes and biofilm forming ability of Burkholderia pseudomallei. Trop Biomed 30: 428–433. PMID: 24198672

46. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, et al. (2008) Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76: 4176–4182. doi: 10.1128/IAI.00318-08 PMID: 18591225

47. O'Driscoll NH, Labovitiadi O, Cushnie TP, Matthews KH, Mercer DK, et al. (2013) Production and evaluation of an antimicrobial peptide-containing wafer formulation for topical application. Curr Microbiol 66: 464–472. doi: 10.1007/s00284-012-0268-3 PMID: 23183933

48. Nguyen LT, Haney EF, Vogel HJ (2011) The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol 29: 46–472. doi: 10.1016/j.tibtech.2011.05.001 PMID: 21680034

49. Bals R (2000) Epithelial antimicrobial peptides in host defense against infection. Respir Res 1: 141–150. PMID: 11667978

50. De Smet K, Contreras R (2005) Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 27: 1337–1347. PMID: 16215847

51. Henzler Wildman KA, Lee DK, Ramamoorthy A (2003) Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 42: 6545–6558. PMID: 12767238

52. Wang Y, Hong J, Liu X, Yang H, Liu R, et al. (2008) Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics. PLoS One 3: e3217. doi: 10.1371/journal.pone.0003217 PMID: 18795096

53. Madhongsa K, Pasan S, Phophetleb O, Nasompag S, Thammasirirak S, et al. (2013) Antimicrobial action of the cyclic peptide bactenecin on Burkholderia pseudomallei correlates with efficient membrane permeabilization. PLoS Negl Trop Dis 7: e2267. doi: 10.1371/journal.pntd.0002267 PMID: 23786532

54. Sieprowska-Lupa M, Mydel P, Krawczyk K, Wojcik K, Puklo M, et al. (2004) Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 48: 4673–4679. PMID: 15561843

55. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI (1998) Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42: 2206–2214. PMID: 9736536

56. Jones AL, Beveridge TJ, Woods DE (1996) Intracellular survival of Burkholderia pseudomallei. Infect Immun 64: 782–790. PMID: 8641782

57. Fujii G, Selsted ME, Eisenberg D (1993) Defensins promote fusion and lysis of negatively charged membranes. Protein Sci 2: 1301–1312. PMID: 8401215